Skip to main content
Premium Trial:

Request an Annual Quote

Amersham to Market, Sell Epoch s MGB Eclipse Line Worldwide

NEW YORK, July 30 - Epoch Bioscience today said it has picked Amersham Biosciences to exclusively market and sell worldwide its MGB Eclipse line of probe systems.

 

Under the terms of the deal, which has certain undisclosed minimum-sales requirements, Amersham will sell the MGB Eclipse line to researchers in the public and private sectors as part of its own genomics-product portfolio.

 

In February, Epoch tapped Glen Research to distribute worldwide its Redmond Red and Yakima Yellow fluorophores, its Eclipse non-fluorescent quencher, and its PPG modified base.

Terms of that agreement call for Glen Research, of Sterling, Va., to repackage Epoch's products into package sizes "suitable for purchase by oligonucleotide synthesis facilities and extends the penetration of these products," Epoch said in a statement at the time.


Epoch also said at the time that Belgian life-science company Eurogentec will use the Yakima Yellow dye and Eclipse quencher technologies to produce custom oligos that it will sell in Europe and Japan.

 

Click here for more information.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.